Jamie Is A 3-Month-Old Female Who Presents With Nonprojectil ✓ Solved

Jamie is a 3-month-old female who presents with nonprojectil

Jamie is a 3-month-old female who presents with nonprojectile regurgitation after feeding. She appears otherwise well, feeds vigorously, and has normal stools. Using this case as context, complete the following: Describe the normal pathophysiology of gastric acid stimulation and production. Explain the changes to gastric acid stimulation and production in gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD), and gastritis. Select one patient factor (genetics, gender, ethnicity, age, or behavior) and explain how that factor might impact the pathophysiology of GERD, PUD, and gastritis. Describe how you would diagnose and prescribe treatment of these disorders for a patient based on the factor you selected. Construct a mind map for gastritis that includes epidemiology, pathophysiology, clinical presentation, diagnosis, and treatment.

Paper For Above Instructions

Introduction

This paper summarizes normal gastric acid physiology and contrasts pathophysiological changes seen in gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD), and gastritis. The selected patient factor is age, applied across the disorders and to the case of Jamie, a 3-month-old with frequent nonprojectile regurgitation. The paper outlines diagnostic approaches and age-appropriate treatments and provides a structured mind map for gastritis (epidemiology, pathophysiology, clinical presentation, diagnosis, treatment).

Normal Pathophysiology of Gastric Acid Stimulation and Production

Gastric acid is produced by parietal (oxyntic) cells in the gastric fundus and body via the H+/K+ ATPase proton pump. Acid secretion is regulated by neural (vagal), endocrine (gastrin), and paracrine (histamine) stimuli. Vagal stimulation (acetylcholine) acts directly on parietal cells and indirectly by stimulating gastrin release from G cells. Gastrin stimulates parietal cells and promotes histamine release from enterochromaffin-like (ECL) cells; histamine acts on H2 receptors on parietal cells, strongly potentiating acid output. Inhibitory signals include somatostatin from D cells and prostaglandins that enhance mucosal blood flow and mucus/bicarbonate secretion (Huether & McCance, 2017).

Alterations in GERD, PUD, and Gastritis

GERD

GERD is driven primarily by transient or sustained dysfunction of the lower esophageal sphincter (LES), impaired esophageal clearance, and, in some patients, hiatal hernia permitting reflux of gastric contents into the esophagus (Vakil et al., 2006). GERD symptoms may occur without increased gastric acid production; rather, reflux of physiologic acid or nonacidic gastric contents causes mucosal injury and symptoms. Acid suppression (e.g., proton pump inhibitors) reduces esophageal exposure and aids healing but does not correct LES dysfunction (Katz et al., 2013).

Peptic Ulcer Disease (PUD)

PUD involves mucosal injury where acid and pepsin overcome mucosal defenses. Major causes include Helicobacter pylori infection and NSAID use. H. pylori disrupts mucus, provokes inflammation, and can increase gastrin-driven acid secretion (duodenal ulcer phenotype) or cause atrophic gastritis with reduced acid (gastric ulcer phenotype) depending on infection pattern (Malfertheiner et al., 2017). NSAIDs inhibit cyclooxygenase and reduce protective prostaglandins, weakening mucosal defense leading to ulceration despite normal or even reduced acid production (Lanas & Chan, 2017).

Gastritis

Gastritis is mucosal inflammation ranging from acute erosive injury to chronic atrophic disease. Acute gastritis is often due to NSAIDs, alcohol, stress, or ischemia and may involve superficial mucosal damage. Chronic gastritis is frequently H. pylori–mediated or autoimmune (parietal cell antibodies), with variable effects on acid secretion: early H. pylori infection may increase acid (predisposing to duodenal ulcer), while chronic corpus-predominant infection can lead to glandular atrophy and hypochlorhydria (Huether & McCance, 2017; Malfertheiner et al., 2017).

Impact of Age on Pathophysiology (Selected Factor)

Age alters the presentation and mechanisms of these disorders. In infants (e.g., Jamie), physiologic gastroesophageal reflux is common due to a short intra-abdominal esophagus, liquid diet, and immature LES tone; acid production is lower than in older children/adults, and symptoms often reflect nonpathologic regurgitation rather than pathological GERD (Nelson Textbook of Pediatrics, 2019). Older adults may have increased prevalence of H. pylori exposure historically, greater NSAID use, decreased mucosal repair capacity, and atypical symptoms (anorexia, anemia) that mask PUD or gastritis (Lanas & Chan, 2017).

Diagnosis and Treatment Tailored by Age

For Infants (Jamie)

Diagnosis: For otherwise thriving infants with nonprojectile regurgitation, clinical evaluation focuses on history (growth, feeding behavior, red flags), physical exam, and observation. Red flags prompting further workup include failure to thrive, severe vomiting, GI bleeding, focal neurologic signs, or respiratory compromise (AAP/NASPGHAN guidance). Routine imaging or endoscopy is not indicated for physiologic reflux (Nelson Textbook of Pediatrics, 2019).

Treatment: Conservative measures are first-line: parental education, reassurance, feeding adjustments (smaller more frequent feeds), positional changes (upright time after feeds), and thickening feeds with cereal if age-appropriate. Acid suppression (H2 blockers or PPIs) is reserved for infants with evidence of pathologic GERD (esophagitis, poor weight gain, apnea suspected reflux) because acid suppression carries infection and adverse-effect risks in infants (Kahrilas et al., 2013).

For Older Children and Adults

Diagnosis: Adults with typical GERD symptoms may undergo an empiric PPI trial or testing for esophageal injury via endoscopy if alarm features exist. For PUD and gastritis, test for H. pylori (urea breath test, stool antigen, or endoscopic biopsy-based tests) and assess NSAID use, medications, and comorbidities (Malfertheiner et al., 2017).

Treatment: GERD—lifestyle measures and acid suppression (PPI) for healing and symptom control; surgical or endoscopic anti-reflux interventions for refractory disease. PUD—stop NSAIDs, eradicate H. pylori with guideline-directed antibiotic/PPI regimens, and provide PPI therapy for ulcer healing (Malfertheiner et al., 2017). Gastritis—treat underlying cause (H. pylori eradication, stop offending drugs), acid suppression for symptom control, and supportive measures (sucralfate when indicated) (Lanas & Chan, 2017).

Mind Map for Gastritis

  • Epidemiology
    • Common worldwide; H. pylori is a leading cause (Malfertheiner et al., 2017).
    • Prevalence increases with age and in populations with poor sanitation.
  • Pathophysiology
    • Acute: NSAIDs, alcohol, stress, ischemia → mucosal erosions.
    • Chronic: H. pylori → chronic inflammation; autoimmune → parietal cell loss and atrophy.
    • Variable acid output: hyperchlorhydria early vs hypochlorhydria with atrophy.
  • Clinical Presentation
    • Epigastric pain/dyspepsia, nausea, vomiting, anorexia, GI bleeding in erosive cases.
    • Older adults may present with anemia, weight loss, or vague symptoms.
  • Diagnosis
    • History and exam, medication review (NSAIDs), H. pylori testing (urea breath, stool antigen, serology, biopsy), endoscopy with biopsy for definitive evaluation.
    • Laboratory: CBC, H. pylori tests, possibly gastric pH assessment in research/complex cases.
  • Treatment
    • Address cause: H. pylori eradication (PPI-based triple or quadruple therapy), stop NSAIDs, treat autoimmune causes supportively.
    • Acid suppression (PPI/H2 blockers), mucosal protectants (sucralfate), dietary and lifestyle modifications.

Conclusion

Understanding normal gastric acid physiology clarifies why GERD, PUD, and gastritis manifest differently. Age fundamentally modifies mechanism and management: infants commonly have physiologic reflux requiring conservative care, while adults may require diagnostic testing and targeted therapies (H. pylori eradication, PPI therapy, NSAID cessation). Accurate diagnosis rooted in age-appropriate evaluation prevents unnecessary interventions and optimizes outcomes.

References

  • Huether SE, McCance KL. Understanding Pathophysiology. 7th ed. Elsevier; 2017.
  • Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease. Am J Gastroenterol. 2006;101(8):1900-1920.
  • Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308-328.
  • Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30.
  • Lanas A, Chan FKL. Peptic ulcer disease. Lancet. 2017;390(10094):613-624.
  • Nelson Textbook of Pediatrics, 21st ed. Kliegman RM, et al., eds. Elsevier; 2019. (Chapters on infant reflux and feeding)
  • American Academy of Pediatrics and NASPGHAN clinical guidance on pediatric GERD and reflux management. Pediatrics. 2018;142(6):e20181113.
  • Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112(2):212-239.
  • Gomollón F, et al. Proton pump inhibitors: benefits and risks. BMJ. 2019;366:l4069.
  • Fashner J, Gitu AC. Diagnosis and treatment of gastroesophageal reflux disease. Am Fam Physician. 2020;101(3):159-165.

Related Assignments